Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Pegvaliase · Palynziq, BMN-165

Other · Protein replacement: phenylalanine · developed by Biomarin Pharm

Approved FDA, May 2018
BMRN Developer
3 Registered trials

What is Pegvaliase?

Pegvaliase-pqpz is a PEGylated phenylalanine ammonia lyase enzyme that converts phenylalanine to ammonia and trans-cinnamic acid, substituting for deficient phenylalanine hydroxylase activity.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Palynziq, BMN-165
Drug type
Other
Targets
phenylalanine
Mechanism
Protein replacement: phenylalanine
Pathways
phenylalanine metabolism
Therapy area
Neurology
Developer
Biomarin Pharm (BMRN)
FDA status
Approved as Palynziq (May 24, 2018), BLA761079 · FDA label
UNII
N6UAH27EUV

✅ FDA-approved uses

From the indications section of the FDA label (version of Mar 2, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07477691 Phase 4 Phenylketonuria Recruiting BMRN
NCT05356377 N/A Phenylketonurias Completed BMRN
NCT04404530 N/A Phenylketonurias Recruiting BMRN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Phenylketonuria

More from Biomarin Pharm

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BMRN page.

Follow BMRN, the company behind Pegvaliase

See BMRN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMRN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.